Home/Pipeline/Oncology Discovery Program

Oncology Discovery Program

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

AMPLY Discovery

About AMPLY Discovery

AMPLY Discovery is an AI-driven drug discovery company founded in 2019, headquartered in Cambridge, UK. It has developed the AMPLYfolio AI platform, which mines digitized natural biological data to discover novel peptides, proteins, and RNAi therapeutics, subsequently producing and testing them via a bioprinting and validation pipeline. The company is pre-clinical and pre-revenue, having secured over $3 million in investment and grant funding from entities like Innovate UK. Its approach aims to democratize and accelerate the discovery of new drugs for complex diseases, starting with oncology and anti-infectives.

View full company profile

Therapeutic Areas

Oncology Infectious Disease

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active